If you have trouble viewing the newsletter, please click here.

Dear ESOP-members!

In this newsletter we would like to present three reports to keep you updated on our activities and to give new impetus to your own daily work.

Yours, Eda Gedikoglu

Chair of publication

ESOP Meetings 2017


The annual NZW was held on 20-22 January 2017 in Hamburg, welcoming oncology pharmacists all over Europe. The conference was very successful, educational and inspiring.
25th NZW - Europe Session was held on 21 January in Hamburg by ESOP. ESOP delegates contributed in an English session, chaired by Prof. Dr. Bernd Meibohm (USA). The sessions took place with the participation of 40 people. At the end of presentations, the participants' were able to discuss the topics. The presentations were 'Chemotherapy induced Nausea and Vomiting: Are We doing enough?' by Fiona Fenech (Malta), 'The Oncology Pharmacist as part of the multiprofessional Palliative Treatment Team' Mirjam Crul (The Netherlands), 'Environmental Contamination with Cytotoxic Drugs in European Hospitals - Masha Project' by Ewelina Korczowska (Poland), 'Pharmacovigilance and the Progress in that Field' by Monika Sonc (Slovenia), 'Biosimilars in Oncology: A crucial Challenge 'by Prof. Dr. Alain Astier (France).


ESOP executive Board meeting was held on 20th January in Hamburg, Germany. The project and activities of ESOP were discussed and discussed. Preliminary assessment of the past year was made by board members. Preparations were made for the road map of the next year and delegate meeting to be held in Amsterdam.


European Cancer Congress 2017 (ECCO2017) which is the only multidisciplinary oncology Congress in Europe was held on 27-28 January 2017 in Amsterdam. The ESOP sessions were held with participation of 100 people on 27th January. The opening speech was made by ESOP president Prof. Klaus Meier.
Oral chemotherapy: Taking the pill, and after? Session presentations were 'Absorption of oral anticancer drugs' by W. Weitschies (Germany), 'Influence of foods and drinks on TKI exposure' by S. Koolen (Netherlands), 'Drug dosing at obesity' by R. Gonec (Czech Republic), 'Dose optimization strategies for small molecules (TKIs)' by C. Bardin (France).
New drugs session presentation was 'New Drugs 2016' by J. Barth (Germany).
Role of the oncology pharmacist in the wards: From clinical cases session presentations were 'The effect of gastrointestinal resections on oncolytic treatment' by N. van Erp (Netherlands), Patients on hemodialysis: Principles of drug elimination by HD, case report by I. Netikova (Czech Republic).
Biosimilars in oncology: Issues under debate session presentations were 'Interchangeability: Also in oncology?' by A. Astier (France), 'Biosimilars in oncology: Will they meet expectations also for oncology?' by P. Cornes (United Kingdom), 'Labeling of biosimilars: Similar to reference product or different?' by F. Megerlin (France). The Klaus-Meier-Award 2017 was given to Dr. Alberto Kosta by Prof. Klaus Meier.

We thank the companies Amgen and Sandoz for their unrestricted educational grant for the ESOP Society Day.


ESOP Society Day was followed by the ESOP Delegate meeting on 27th January in Amsterdam, The Netherlands. Chairs gave presentations about the projects they were responsible for and made proposals for the next steps. Some delegates could present reports on special activities in their country. The general activities of ESOP planned for the next year were discussed.


  • EPIC
  • education


  • Quapos5
  • Clean working
  • Spill Kit
  • Webinars


The safe use of high risk drugs is as important for patients as it is for all the staff working on these drugs. Cytotoxic drugs should be easily identifiable by all staff involved in the use of the drug. There should be warning labels on the outer packages of the drugs that clearly indicate that the products are cytotoxic. ESOP recommends the use of 'YELLOW HAND' to increase the awareness of the danger that may occur during the transfer of cytotoxic drugs, according to safe delivery methods in QUAPOS GUIDELINES.

The Quality Standard for the Pharmaceutical Service (QuapoS, 2014, 5th edition), translated into 28 national languages, includes the following wording:

3.1.2. Acceptance of Drug Deliveries

Cytostatics deliveries may be accepted only by trained pharmacy staff. The packages or the sealed cytostatics, respectively, are to be opened at a separate location. The staff is wearing suitable protective equipment. Noticeable problems such as breakage, contamination etc. must be documented and reported to the manufacturer and to the workplace safety officer. The cause should be identified and eliminated as quickly as possible.

The commentary includes the following explanation:

Acceptance of goods

Cytostatics deliveries should be transported to the cytostatics unpacking site by the supplying company, separate from other products, delivered with unambiguous labeling ("Yellow Hand", see www.esop.eu) and unopened.

The following section goes on to say:

3.1.3. Returning to the manufacturer

When consignments of hazardous medical products are returned to a manufacturer, e.g. in conjunction with a complaint, the procedure should be discussed first with the recipient. Packaging must ensure safe transport and safe removal. The consignment is to be labeled in accordance with legal requirements and display the Yellow Hand.

'YELLOW HAND' should become a universal sign for all people who will come into contact with cytotoxic drugs during transfer. More and more companies in the world are supporting this initiative. ESOP is pleased to see that this initiative is widely used by many companies in many countries not only in Europe but also outside Europe.

New examples from ALGERIA, MOROCCO & ITALY




11th Masterclass in Oncology Pharmacy

We thank the following companies for their unrestricted educational grant for the 11th Masterclass in Oncology Pharmacy, 22nd - 26th May 2017

More information »

* EUR 1500,00

If you don't want to recieve any further ESOP Newsletters, please click to unsubscribe.